SCOLR Pharma, Inc. Form 4										
February 22, 2007										
							PPROVAL			
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							Expires: January 31, 2005 Estimated average burden hours per response 0.5			
<i>See</i> Instruction 30(h) of the Investment Company Act of 1940 1(b).										
(Print or Type Responses)										
1. Name and Address of Reporting TAGLICH MICHAEL N	Symbol	2. Issuer Name and Ticker or Trading Symbol SCOLR Pharma, Inc. [DDD]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (I	(Middle) 3. Date of Earliest Transaction				(ene					
(Month/Day/Year) C/O SCOLR PHARMA, INC., 3625 - 132ND AVENUE S.E., SUITE 400					X Director Officer (giv below)		% Owner her (specify			
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
BELLEVUE, WA 98006 Form filed by More than One Reporting Person							eporting			
(City) (State)	(Zip) Tak	ole I - Non-I	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned			
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Report on a separate line	e for each class of sec	urities benef	Perso inform requir	ns who rest ation cont ed to respo ys a curre	or indirectly. spond to the colle cained in this form ond unless the for ntly valid OMB co	are not m	SEC 1474 (9-02)			

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: SCOLR Pharma, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Dispose	ed (A) or ed of (D) 3, 4, and				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shares
Common Stock Warrant (right to buy)	\$ 7.5	04/17/2006		A	5,500 (1)		04/17/2006	04/17/2011	Common Stock	5,50(
Common Stock Warrant (right to buy)	\$ 7.5	02/21/2007		J <u>(3)</u>		5,500	04/17/2006	04/17/2011	Common Stock	5,500

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
TAGLICH MICHAEL N C/O SCOLR PHARMA, INC. 3625 - 132ND AVENUE S.E., SUITE 400 BELLEVUE, WA 98006	Х					
Signatures						
Michael N. Taglich by Alan M. Mitchel, Attorney-in-Fact		02/	21/2007			
**Signature of Reporting Person			Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person is a stockholder and executive officer of Taglich Brothers, Inc. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- (2) Acquired by Taglich Brothers, Inc. as partial consideration received for placement agent services in connection with the issuer's registered direct offering of 2,370,100 shares of its common stock completed on April 21, 2006.
- (3) The warrants were distributed by Taglich Brothers, Inc. to certain non-reporting employees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.